Medplus Health Services Ltd

MEDPLUS

Watchlist

AI Mode

‌

Market Cap

₹ 9,684 Cr

P/E

49.64

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

EXCEPTIONAL

Profitability

MODERATE MARGIN

Technicals

Bullish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

MedPlus Health Services Limited is primarily engaged in pharmaceutical retail, diagnostic services, and pathology services with a strong focus on expanding its retail pharmacy network and offering MedPlus-branded pharmaceutical products.

Despite facing challenges, MedPlus has maintained a growth trajectory by opening 145 new stores in Q2 FY '26 and planning 600 additional outlets over the fiscal year. This expansion strategy strongly positions the company in the retail pharmacy market.

The company recorded a substantial Y-o-Y revenue growth of 6.3% on a net basis in Q2 FY '26, with its pharmacy operations now constituting 99% of its total revenue. This underlines the importance of its pharmacy business to overall financial performance.

MedPlus has improved its margin profile with an operating EBITDA of INR 887 million, representing 5.3% of its consolidated revenue, reflecting effective cost management and operational efficiency improvements.

Private label products have seen impressive growth, with private label pharma sales reaching 19.8% of GMV in the current quarter, marking a strategic shift towards higher-margin own-brand products.

Sector

Retail

Industry

Trading - Medium / Small

Market Cap

9,684 Cr

Volatility

Low Risk

P/E Ratio

49.6

Industry P/E

35.9

PEG Ratio

3.8

P/B Ratio

5.3

52W High

1,052.05

52W Low

603.00

Sales CAGR

9.13%

69.78%

138.41%

10Y

89.68%

Profit CAGR

129.08%

93.36%

—

10Y

—

ROE

TTM

10.57%

5.52%

6.11%

10Y

6.07%

ROCE

TTM

11.47%

7.73%

8.55%

10Y

9.42%

Technicals

‌

Forecasts

No. of Analysts

12

1Y Price Target

1105.00 ▲ 38.00%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Nov 14, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
MEDPLUS	807.25	9,684 Cr	49.64	5.25	0.00	10.57	11.47	5.46
JSLL	742.00	9,209 Cr	275.41	73.20	0.15	0.00	0.00	—
LLOYDSENT	58.51	8,432 Cr	26.39	2.26	0.15	8.52	11.91	6.36
MMTC	56.10	8,379 Cr	118.85	4.36	0.00	3.66	6.64	5.85
HONASA	256.85	8,360 Cr	63.60	6.58	0.00	10.35	12.95	6.94
ETHOSLTD	3031.00	8,136 Cr	85.60	5.67	0.00	6.63	8.64	4.44
REDTAPE	126.30	6,987 Cr	38.65	8.15	1.78	21.08	17.42	7.89

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	1,284	1,409	1,441	1,491	1,489	1,576	1,561	1,510	1,543	1,679
Expenses	1,213	1,324	1,350	1,385	1,395	1,452	1,429	1,373	1,412	1,530
Operating Profit	71	85	92	106	94	124	133	136	131	149
OPM %	5.56	6.04	6.37	7.10	6.30	7.90	8.49	9.03	8.47	8.86
Other Income	9.39	10	9.79	10	8.71	12	13	16	15	17
Interest	23	24	25	25	25	25	26	27	27	29
Depreciation	52	55	57	59	60	63	62	64	66	69
Profit Before Tax	5.05	16	20	32	18	48	57	61	53	69
Tax %	25.54	11.56	31.36	-4.94	19.34	19.02	18.96	16.03	19.75	19.48
Net Profit	3.77	15	14	34	14	39	46	51	42	56
EPS in Rs	0.32	1.21	1.14	2.78	1.20	2.22	3.81	4.30	3.53	4.63

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	2,012	2,132	2,273	2,871	3,069	3,779	4,558	5,625	6,136	6,190
Expenses	1,942	2,073	2,216	2,737	2,853	3,507	4,292	5,271	5,649	5,666
Operating Profit	70	59	57	134	217	272	266	354	487	524
OPM %	3.48	2.75	2.50	4.66	7.06	7.21	5.83	6.29	7.94	8.47
Other Income	8.45	7.22	9.83	17	22	31	46	40	49	55
Interest	39	28	16	47	55	66	83	96	103	105
Depreciation	11	12	14	75	88	119	182	224	250	255
Profit Before Tax	28	26	37	29	95	118	47	73	183	218
Tax %	62.09	-65.18	42.82	93.89	33.64	19.69	-6.24	10.71	18.03	18.34
Net Profit	11	42	21	1.79	63	95	50	66	150	178
EPS in Rs	—	—	—	—	—	8.49	4.16	5.44	11.53	16.26
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.17	0.17	0.19	0.19	0.19	0.45	24	24	24	24
Reserves	137	149	303	325	528	730	1,394	1,467	1,554	1,717
Borrowings	216	204	162	104	477	590	815	900	1,010	1,120
Other Liabilities	156	185	179	243	344	245	361	406	417	500
Total Liabilities	509	538	644	673	1,349	1,566	2,594	2,797	3,005	3,360
Fixed Assets	77	81	83	90	419	517	799	1,138	1,242	1,296
CWIP	3.49	0.35	0.93	1.43	4.94	5.54	20	25	11	16
Investments	0.04	0.05	0.00	0.00	0.25	0.03	0.03	0.03	0.00	0.00
Other Assets	429	457	560	582	924	1,043	1,775	1,633	1,752	2,047
Total Assets	509	538	644	673	1,349	1,566	2,594	2,797	3,005	3,360

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-17	35	32	82	-6.59	2.89	170	90	144	540
Cash from Investing Activity	-32	-15	-18	-20	-28	-35	-703	429	-83	-318
Cash from Financing Activity	35	-30	-0.88	-72	90	-5.63	440	-170	-198	-228
Net Cash Flow	-14	-10	14	-10	56	-37	-93	350	-137	-5.16

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	40.54%	40.51%	40.49%	40.46%	40.49%	40.43%	40.42%	40.41%	40.40%	40.36%	40.34%	40.31%
FIIs	3.96%	4.50%	4.87%	12.37%	12.98%	14.96%	14.86%	14.73%	15.24%	15.61%	16.43%	16.54%
DIIs	28.86%	28.21%	28.18%	25.52%	25.21%	22.49%	22.19%	27.99%	25.66%	26.20%	26.05%	26.53%
Public	26.64%	26.79%	26.46%	21.64%	21.32%	22.12%	22.53%	16.86%	18.69%	17.83%	17.18%	16.61%
Total Shareholders	74,702	73,512	70,017	66,430	66,048	74,976	76,934	87,328	83,912	83,439	81,742	78,337

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 03, 2025	Graviton research capital llp	Bulk	Buy	836.74	56.38 Cr	6,73,825	0.56
Nov 03, 2025	Graviton research capital llp	Bulk	Sell	837.39	56.40 Cr	6,73,497	0.56
Jan 03, 2025	Madhukar reddy gangadi	Insider - Promoter	Pledge	847.20	162.49 Cr	19,17,987	1.60
Jan 03, 2025	Lone furrow investment privat...	Insider - Promoter	Pledge	831.75	41.59 Cr	5,00,000	0.41
Dec 30, 2024	Lone furrow investment privat...	Insider - Promoter	Revoke	839.15	1,288.56 Cr	1,53,55,562	12.8
Dec 24, 2024	Madhukar reddy gangadi	Insider - Promoter	Pledge	865.75	1,162.91 Cr	1,34,32,413	11.2
Nov 18, 2024	Invesco india large & mid cap...	Bulk	Buy	700.00	79.22 Cr	11,31,734	0.94
Nov 18, 2024	Franklin templeton mf india s...	Bulk	Buy	700.00	54.46 Cr	7,77,950	0.64
Nov 18, 2024	Franklin templeton mf flexi c...	Bulk	Buy	700.00	58.09 Cr	8,29,917	0.69
Nov 18, 2024	Sbi mutual fund	Bulk	Sell	700.00	70.00 Cr	10,00,000	0.83

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Regulatory Filing

2 days ago

MedPlus Health Services Drug License Suspension

Optival Health Solutions, a subsidiary of MedPlus Health Services, received three suspension orders for drug licenses in Maharashtra, resulting in potential revenue loss.

Regulatory Filing

5 days ago

Drug License Suspension for Optival Health Solutions

Optival Health Solutions has received a five-day suspension order for its Drug License in Karnataka, resulting in an estimated revenue loss of Rs 2.40 lacks.

Regulatory Filing

5 days ago

Favorable High Court Order for Optival Health Solutions

Optival Health Solutions Private Limited, a subsidiary of MedPlus, received a favorable order from the Telangana High Court regarding a disputed tax assessment.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Showing 1 - 8 of 18

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

Private label products have seen impressive growth, with private label pharma sales reaching 19.8% of GMV in the current quarter, marking a strategic shift towards higher-margin own-brand products.

Sector

Retail

Industry

Trading - Medium / Small

Market Cap

9,684 Cr

Volatility

Low Risk

P/E Ratio

49.6

Industry P/E

35.9

PEG Ratio

3.8

P/B Ratio

5.3

52W High

1,052.05

52W Low

603.00

Sales CAGR

9.13%

69.78%

138.41%

10Y

89.68%

Profit CAGR

129.08%

93.36%

—

10Y

—

ROE

TTM

10.57%

5.52%

6.11%

10Y

6.07%

ROCE

TTM

11.47%

7.73%

8.55%

10Y

9.42%